Search
Temporomandibular Joint Dysfunction
go.drugbank.com/conditions/DBCOND0039544Drugs: Botulinum toxin type ASynonyms: Costen's complexEsketamine
go.drugbank.com/drugs/DB11823ApprovedInvestigationalThe FDA approved ketamine (Ketalar) in 1970. … [L5593] Esketamine may prove to be a promising treatment for patients diagnosed with major depressive disorder who have not experienced an improvement in symptoms despite treatment with various medications
Categories: Non-Competitive N-Methyl D-Aspartate (NMDA) Receptor AntagonistsProducts: Eskelan 25 mg/ml-Injektions-/Infusionslösung in Ampullen, Eskelan 25 mg/ml-Injektionslösung in DurchstechflaschenBemiparin
go.drugbank.com/drugs/DB09258ApprovedInvestigationalWithdrawnBemiparin is an antithrombotic and belongs to the group of drugs known as the low molecular weight heparins (LMWH). … Interestingly, current research is underway for the potential benefit of bemiparin in the treatment of tumors and diabetic foot ulcers [L1468, A7866].
Products: Ivor 2500 IE Anti-Xa/0,2 ml Injektionslösung in Fertigspritzen, Ivor 3500 IE Anti-Xa/0,2 ml Injektionslösung in FertigspritzenTubulin gamma-1 chain
go.drugbank.com/bio_entities/BE0003713TargetHumansGamma-tubulin is a key component of the gamma-tubulin ring complex (gTuRC) which mediates microtubule nucleation (PubMed:38305685, PubMed:38609661, PubMed:39321809).
Synonyms: Gamma-tubulin complex component 1Anisotropine methylbromide
go.drugbank.com/drugs/DB00517Approvedaction on the bile ducts and gallbladder. … Its use as treatment adjunct in peptic ulcer has been replaced by the use of more effective agents.
Avalglucosidase alfa
go.drugbank.com/drugs/DB16099ApprovedInvestigationalGAA is an essential enzyme that hydrolyzes glycogen into free glucose for use in cellular functions. … [A232955] In clinical trials, avalglucosidase alfa improved lung function in patients with Pompe disease.
Simeprevir
go.drugbank.com/drugs/DB06290ApprovedWithdrawnSustained virologic response 12 weeks after planned end of treatment (SVR12) was achieved in 170/176 (97%) subjects without cirrhosis treated with 12 weeks simeprevir in combination with sofosbuvir (FDA … The SVR12 was 83% (29/35) in treatment-naïve patients and 86% (19/22) in relapsing patients.
Polymyxin B
go.drugbank.com/drugs/DB00781ApprovedInvestigationalVet approvedPolymyxin B was discovered in the 1940s[A176429]. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes[A176426].
Mixtures: H E Buddy Antibiotic Maximum Strength Plus Pain Relief, Bacitracin-N OintmentEplontersen
go.drugbank.com/drugs/DB16199ApprovedInvestigationalEplontersen is a transthyretin-directed antisense oligonucleotide with 3 covalently linked e N-acetyl galactosamine residues for hepatic delivery. … This approval was based on positive results demonstrated in the 35-week interim analysis from the Phase 3 NEURO-TTRansform study, where a consistent improvement in the Neuropathy Impairment Score +7 (mNIS
Spesolimab
go.drugbank.com/drugs/DB15626ApprovedInvestigationalin December 2022 for the treatment of flares in adult patients with generalized pustular psoriasis. … Spesolimab is an interleukin-36 (IL-36) receptor antagonist.